We
deliver your message to your target audience.
Our 200 million OPT-IN e-mails and 130 million
data files are targeted using cutting edge technology
with over 12 million specifically targeted to
the financial community.
About Us CellCyte Genetics Corporation
is an emerging biotechnology leader focused
on the development and commercialization
of breakthrough stem cell-enabling therapeutic
products. CellCyte’s programs capitalize
on a large body of recent data generated
in preclinical and clinical studies performed
by leading experts in the stem cell and
regenerative medicine space. These data
have demonstrated the benefit of stem cells
while highlighting the need to deliver and
retain higher numbers of stem cells to achieve
a greater clinical benefit. CellCyte’s
therapeutic advancements are expected to
make it possible, for the first time, to
efficiently deliver stem cells to a desired
location for repair and regeneration.
CellCyte’s
experienced management team, unique technology,
and strong intellectual property position
provide solid footing for the Company
to become a leader in regenerative medicine.
Glycoprotein platform: •
Preclinical research platform licensed from
the Department of Veterans Affairs which
targets and delivers stem cells to the heart.
• Our lead delivery candidates are
derived from a naturally occurring human
plasma protein, with anticipated low toxicity.
